Short Interest in Senseonics Holdings Inc (SENS) Grows By 17.5%
Senseonics Holdings Inc (NYSEAMERICAN:SENS) saw a large increase in short interest in January. As of January 31st, there was short interest totalling 4,635,391 shares, an increase of 17.5% from the January 12th total of 3,946,300 shares. Approximately 9.6% of the shares of the stock are short sold. Based on an average daily trading volume, of 667,199 shares, the short-interest ratio is presently 6.9 days.
Shares of Senseonics (NYSEAMERICAN SENS) traded up $0.03 during midday trading on Friday, hitting $2.55. The company had a trading volume of 501,547 shares, compared to its average volume of 533,430. The stock has a market cap of $358.30 and a PE ratio of -5.10. The company has a current ratio of 2.93, a quick ratio of 2.81 and a debt-to-equity ratio of 0.76. Senseonics has a 52 week low of $1.26 and a 52 week high of $3.67.
In related news, major shareholder Peter J. Barris sold 139,645 shares of the firm’s stock in a transaction dated Friday, December 8th. The stock was sold at an average price of $2.63, for a total transaction of $367,266.35. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 34.10% of the company’s stock.
Separately, Canaccord Genuity reissued a “buy” rating on shares of Senseonics in a report on Wednesday, November 1st.
WARNING: “Short Interest in Senseonics Holdings Inc (SENS) Grows By 17.5%” was published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://theolympiareport.com/2018/02/09/short-interest-in-senseonics-holdings-inc-sens-grows-by-17-5.html.
Senseonics Holdings, Inc is a medical technology company. The Company focuses on the design, development and commercialization of glucose monitoring systems. The Company operates through glucose monitoring systems segment. It offers a continuous glucose monitoring (CGM) system, Eversense, which is designed an implantable CGM system designed to continually measure glucose levels in people with diabetes.
Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.